NEW BRUNSWICK, N.J., Aug. 26, 2021 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced it is accepting applications for its 2022 Women in STEM2D (WiSTEM2D) Scholars Award. The award, which aims to support assistant or associate academic professors in the disciplines of Science, Technology, Engineering, Math, Manufacturing and Design, provides recipients with three years of mentorship from leaders at Johnson & Johnson and a total $150,000 ($50,000 each year). The deadline for applications is September 27, 2021 at 9 a.m. HST, and guidelines and additional details are available here: https://www.jnj.com/wistem2d-university-scholars.
Launched in June 2017, the Johnson & Johnson WiSTEM2D Scholars Award aspires to fuel development of female STEM2D leaders, and inspire career paths in STEM2D, by supporting the research of the awarded women in their respective STEM2D fields.
“COVID-19 has shown us that investments in research are critical to advance health for humanity and, as we begin to emerge from the pandemic, there is a great need for continued progress and innovation aimed at a healthier, safer and more equitable world,” said Cat Oyler, Vice President, Clinical Transformation, Immunology and Integration Leader, Momenta Pharmaceuticals, Inc. and WiSTEM2D University Sponsor. “Research shows that the pandemic disproportionally affected women in WiSTEM2D, with 70% unable to obtain funding, making this award more crucial than ever.”
An independent External Advisory Board will select the 2022 winners, each of whom will represent one of the STEM2D disciplines. Last year, more than 650 highly qualified applicants from across the world applied for the award.
In order to apply for the 2022 WiSTEM2D Scholars Award, the applicant must:
- Submit a university or school department head letter of recommendation (Each University/Institution can support one applicant per STEM2D discipline; 6 applicants in total).
- Write 1,000 words detailing the proposed area of research. One additional page can be added for images, or references.
- Submit her resume (three pages, font size 11), including a list of publications, presentations, abstracts, current financial support already obtained, other folio work and two references.
- Submit a brief outline of the budget for proposed research.
For more information and to apply for the 2022 Awards, visit: https://www.jnj.com/wistem2d-university-scholars.
About Johnson & Johnson WiSTEM2D
Building a diverse STEM2D community is one approach Johnson & Johnson is taking as part of a broader effort to accelerate the development of women leaders and support women at all stages of their life to improve global health and well-being and drive sustainable economic growth. Johnson & Johnson launched the WiSTEM2D (Women in Science, Technology, Math, Manufacturing and Design) program in 2015 to increase the representation of women in science and technical fields. The program’s multifaceted approach is designed to engage females at three pivotal development stages in their lives:
- Youth Programs (Ages 5 to 18 years): Johnson & Johnson is partnering with organizations to align curriculum in schools, augment program-based learning and engage Johnson &
- Johnson employees around the world as mentors to students.
University Talent: Johnson & Johnson is partnering with leading academic institutions to develop high-impact strategies for increasing the number of women enrolling in and graduating with STEM2D programs and degrees. At the graduate level, Johnson & Johnson has implemented to STEM2D Scholars Award to increase the number of women pursuing research in STEM2D fields. - Professionals: Johnson & Johnson is identifying and implementing best practices for attracting and retaining the world’s best technical female talent in STEM2D careers.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding development of a potential preventive vaccine for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
Media Contacts:
Michael Nge, APCO Worldwide
[email protected]
Maggie McGarvey, APCO Worldwide
[email protected]
SOURCE Johnson & Johnson
